文献速递细胞病理与分子病理胸部病理

非小细胞肺癌心包积液的临床病理与分子特征

Clinicopathological and molecular characterization of non-small cell lung cancer with pericardial effusions.
PubMed 文献 · Cancer Cytopathol · 2025-01-01

该回顾性研究分析80例非小细胞肺癌合并心包积液患者,按ISRSFC分类并检测分子改变与生存。结果显示63.75%标本为恶性,p53突变最常见(59.1%),细胞学阴性是独立预后因素,免疫治疗组生存最长(9.07个月)。

要点

  • ISRSFC分类对NSCLC心包积液评估至关重要,63.75%为恶性。
  • p53突变(59.1%)、KRAS(34.1%)和EGFR(15.9%)是常见分子改变。
  • 细胞学阴性状态是独立预后因素,免疫治疗可延长IV期患者生存。

核心结论

  • 细胞学评估和ISRSFC分类对NSCLC相关心包积液至关重要。
  • 整合细胞学、免疫组化和分子谱的多学科方法对优化管理和预后必不可少。

研究设计与样本

  • 回顾性分析80例NSCLC合并心包积液患者15年临床数据。
  • 心包积液标本按ISRSFC分类,分析人口学、分子改变、细胞病理、组织学和生存结局。

主要发现

  • 36例(45%)为女性,90%为IV期,58例(72.5%)有吸烟史,22例(27.5%)出现心包填塞。
  • 肺腺癌占87.5%;ISRSFC分类:25%阴性(NFM)、7.5%意义不明的不典型(AUS)、3.75%可疑恶性(SFM)、63.75%恶性(MAL)。
  • 57例免疫组化中甲状腺转录因子1(65%)最常阳性;分子分析p53突变(59.1%)最常见,其次KRAS(34.1%)和EGFR(15.9%)。
  • Kaplan-Meier分析显示NFM患者生存显著优于非NFM(MAL、SFM和AUS;p = .0036);血性心包积液和心包填塞与更差结局相关。
  • IV期患者中免疫治疗组生存最长(9.07个月;p = .017);Cox回归证实细胞学阴性状态为独立预后因素。

临床怎么用

  • 对NSCLC患者的心包积液应进行细胞学评估并按ISRSFC分类。
  • 结合免疫组化和分子检测(如p53、KRAS、EGFR)可指导管理。
  • 细胞学阴性状态提示较好预后,血性积液和心包填塞提示不良预后。
  • IV期患者可考虑免疫治疗以延长生存。

局限性

  • 回顾性研究,样本量80例,来自单中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cytological evaluation is essential for assessing pericardial effusions (PEs) in non-small cell lung cancer (NSCLC). This study retrospectively examined the clinicopathological, molecular, and prognostic characteristics of patients with NSCLC with PE. METHODS: Clinical data from 80 patients with NSCLC with PE treated at an academic center over the course of 15 years were reviewed. PE specimens were categorized according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC). The analysis included patient demographics, molecular alterations, cytopathology, histology, and survival outcomes. RESULTS: Of the 80 patients, 36 (45%) were female and 90% had stage IV disease. A smoking history was noted in 58 patients (72.5%), and 22 patients (27.5%) presented with tamponade. Lung adenocarcinoma predominated (87.5%). The ISRSFC categorized 25% of the specimens as negative for malignancy (NFM), 7.5% as atypia of undetermined significance (AUS), 3.75% as suspicious for malignancy (SFM), and 63.75% as malignant (MAL). Immunohistochemistry in 57 specimens identified thyroid transcription factor 1 (65%) as the most frequently positive marker. Molecular analysis revealed p53 mutations (59.1%) as the most prevalent, followed by KRAS (34.1%) and EGFR (15.9%). Kaplan-Meier analysis showed significantly better survival for NFM patients than non-NFM patients (MAL, SFM, and AUS; p = .0036). Bloody PEs and tamponade were associated with worse outcomes. The immunotherapy group achieved the most prolonged survival among stage IV patients (9.07 months; p = .017). Cox regression confirmed cytology-negative status as an independent prognostic factor. CONCLUSIONS: Cytological evaluation and ISRSFC classification are crucial for NSCLC-associated PEs. A multidisciplinary approach integrating cytology, immunohistochemistry, and molecular profiling is essential for optimal management and prognosis.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Ma W, Rodrigues Simoes NJ, Seery PP, et al. Clinicopathological and molecular characterization of non-small cell lung cancer with pericardial effusions. Cancer Cytopathol. 2025. PMID: 40227522. doi:10.1002/cncy.70015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。